3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Gastrointestinal
1
Conditions
Febrile Neutropenia
6
Neutropenia
4
Neoplasms
4
Fever
4
Infections
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Hematologic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Stomach Neoplasms
1
Recurrence
1
Pseudomonas Infections
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Liver Neoplasms
1
Interventions
pembrolizumab
287
Nivolumab
258
Ipilimumab
236
aldesleukin
134
Cyclophosphamide
134
Interleukin-2
104
Temozolomide
75
Dacarbazine
74
trametinib
70
Vemurafenib
69
fludarabine
67
dabrafenib
65
fludarabine phosphate
61
sargramostim
44
binimetinib
44
Radiosurgery
44
Biopsy
43
Paclitaxel
42
Bevacizumab
42
incomplete Freund's adjuvant
39
encorafenib
37
Radiotherapy
36
Cisplatin
36
CTLA-4 Antigen
36
atezolizumab
35
Carboplatin
35
cobimetinib
32
Magnetic Resonance Spectroscopy
32
Introns
30
Specimen Handling
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Melanoma
×
Vancomycin
×
Clear all
NCT04208958
2025-10-27
ConsortiumIO
Vedanta Biosciences, Inc.
Phase 1/2
Completed
56 enrolled
11 charts
NCT06540391
2025-09-26
MELODY-1
Microbiotica Ltd
Phase 1
Active not recruiting
41 enrolled